| Market Cap | 49.69M | P/E | - | EPS this Y | 3.80% | Ern Qtrly Grth | - |
| Income | -41.97M | Forward P/E | -1.01 | EPS next Y | -45.00% | 50D Avg Chg | -7.00% |
| Sales | 6.77M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -36.00% |
| Dividend | N/A | Price/Book | 0.66 | EPS next 5Y | - | 52W High Chg | -74.00% |
| Recommedations | 1.40 | Quick Ratio | 6.51 | Shares Outstanding | 26.29M | 52W Low Chg | 38.00% |
| Insider Own | 28.72% | ROA | -22.06% | Shares Float | 12.07M | Beta | 0.63 |
| Inst Own | 33.17% | ROE | -61.18% | Shares Shorted/Prior | 193.84K/322.14K | Price | 1.89 |
| Gross Margin | 48.56% | Profit Margin | - | Avg. Volume | 671,325 | Target Price | - |
| Oper. Margin | -1,541.64% | Earnings Date | Jun 6 | Volume | 12,870 | Change | -1.56% |
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
| Jefferies | Buy | Apr 19, 21 |
| JP Morgan | Overweight | Apr 19, 21 |
| SVB Leerink | Outperform | Apr 19, 21 |